Nicholas Bingham

Nicholas Bingham serves as an Adjunct Research Fellow at the Australian Centre for Blood Diseases, Monash University, focusing on hematological malignancies and diagnostic innovation. His work integrates proteomics, liquid biopsy development, and molecular diagnostics to address challenges in multiple myeloma detection and monitoring.

Dr. Bingham's research spans hematology, oncology, and proteomics, with emphasis on:

• Liquid biopsy optimization for early cancer detection
• Extracellular vesicle characterization in tumor microenvironments
• Mass spectrometry-based minimal residual disease assessment
• Molecular stratification of high-risk myeloma subtypes

His publications demonstrate consistent advancement in translating proteomic findings into clinical diagnostics, particularly through blood-based biomarker discovery.

Current research trends emphasize non-invasive monitoring techniques, with recent work establishing DNA copy number variations and clonotypic assays as critical tools for identifying smouldering myeloma progression. Collaborative projects integrate flow cytometry, mass spectrometry, and genomic analysis to refine risk stratification models.

Dr. Bingham leads the 2024-2025 project Establishing blood-based liquid biopsies for early detection of high-risk multiple myeloma as Primary Chief Investigator, collaborating with Spencer, Reynolds, and Mithraprabhu. This NHMRC-funded initiative builds on his team's prior work in extracellular vesicle proteomics and MYC DNA analysis.

His laboratory work centers on the Australian Centre for Blood Diseases' myeloma research program, utilizing:

• Plasma extracellular vesicle isolation protocols
• Mass spectrometry clonotypic assays (EasyM)
• EuroFlow-based minimal residual disease tracking
• Stromal cell interaction models

Future directions include validating liquid biopsy markers for clinical implementation and expanding high-risk myeloma detection to pre-symptomatic stages.